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Abstract
Background: Our intention was to compare the rate of immunological progression prior to antiretroviral therapy
(ART) and the virological response to ART in patients infected with subtype B and four non-B HIV-1 subtypes (A, C,
D and the circulating recombinant form, CRF02-AG) in an ethnically diverse population of HIV-1-infected patients in
south London.
Methods: A random sample of 861 HIV-1-infected patients attending HIV clinics at King’s and St Thomas’ hospitals’
were subtyped using an in-house enzyme-linked immunoassay and env sequencing. Subtypes were compared on
the rate of CD4 cell decline using a multi-level random effects model. Virological response to ART was compared
using the time to virological suppression (< 400 copies/ml) and rate of virological rebound (> 400 copies/ml)
following initial suppression.
Results: Complete subtype and epidemiological data were available for 679 patients, of whom 357 (52.6%) were
white and 230 (33.9%) were black African. Subtype B (n = 394) accounted for the majority of infections, followed
by subtypes C (n = 125), A (n = 84), D (n = 51) and CRF02-AG (n = 25). There were no significant differences in
rate of CD4 cell decline, initial response to highly active antiretroviral therapy and subsequent rate of virological
rebound for subtypes B, A, C and CRF02-AG. However, a statistically significant four-fold faster rate of CD4 decline
(after adjustment for gender, ethnicity and baseline CD4 count) was observed for subtype D. In addition, subtype
D infections showed a higher rate of virological rebound at six months (70%) compared with subtypes B (45%, p =
0.02), A (35%, p = 0.004) and C (34%, p = 0.01)
Conclusions: This is the first study from an industrialized country to show a faster CD4 cell decline and higher rate
of subsequent virological failure with subtype D infection. Further studies are needed to identify the molecular
mechanisms responsible for the greater virulence of subtype D.
Introduction
The world-wide HIV epidemic has been characterized
by increasing genetic diversity, with multiple distinct
viral subtypes, as well as sub-subtypes, and circulating
recombinant forms (CRFs) [1-3]. At present, specific
subtypes and CRFs are found more frequently in certain
countries or regions of the world. Globally, the main
variants are subtype C, which predominates in south
and east Africa, followed by subtype A and the recombi-
nant form CRF02-AG in west and west-central Africa.
Although subtype B dominates in North America,
western Europe and Australia, the recent epidemiology
of HIV-1 infection in the UK and many western Eur-
opean countries has been characterized by a marked
increase in the prevalence of non-B subtypes and several
CRFs [4-9]. In the UK, the number of new diagnoses
due to heterosexually acquired infection has risen
almost four-fold since 1996. The majority (> 95%) of
these infections are likely to have been acquired abroad,
mainly in sub-Saharan Africa but also in the Caribbean
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neous pattern of subtypes in the heterosexually acquired
HIV-1-infected population in the UK [10]. There is also
evidence for onward transmission of these non-B HIV-1
strains within the UK [11].
Given the increasing subtype diversity in various sub-
populations, the potential for the emergence of novel
genetic variants, and the increasing availability of antire-
troviral therapy (ART) worldwide, it has become even
more important to establish the clinical implications of
subtype variation [12-14]. Limitations of previous studies
on the impact of subtype on disease progression have
included a small sample size, use of seroprevalent cohort
data, and the tendency to analyze non-B subtypes as a
single group [15-25].
However, several recent studies from sub-Saharan
Africa have found higher rates of disease progression
in individuals infected with subtype D virus [16,22-25].
There remains still very limited data on HIV-1 subtype
differences in the response to ART [26-30]. The main
objectives of our study were to compare the rate of
disease progression, based on rate of CD4 decline prior
to ART, and the initial and subsequent virological
response to ART in an ethnically diverse population in
south London infected with subtype B and the most
c o m m o nn o n - BH I V - 1s u b t y p e s( A ,C ,Da n dC R F 0 2 -
AG).
Methods
Study population
King’s College Hospital and St Thomas’ Hospital HIV
clinics are based in the inner London boroughs of Lam-
beth, Southwark and Lewisham. In addition to contain-
ing a large migrant population from sub-Saharan Africa
and a significant black Caribbean community, these
areas have the highest rate of new HIV diagnoses in the
UK. The two clinics care for a heterogeneous population
of almost 3000 HIV-1-infected patients, a large propor-
tion of whom originate from sub-Saharan Africa. We
selected an approximately 50% random sample of 861
patients (456 from King’s College Hospital and 405
from St Thomas’ Hospital) based on all adult (≥ 18
years) HIV-1-infected patients who had attended the
HIV clinic at either site over a one-year period between
May 1999 and May 2000.
Data collection
HIV-1-infected patients receiving antiretroviral therapy
are seen routinely at three- to four-month intervals for
clinical evaluation, monitoring of CD4 count, viral load,
haematology and biochemistry. Those not on antiretro-
viral therapy are reviewed every three to six months.
The criteria for initiation of ART are the presence of a
CD4 cell count of < 350 cells/mm
3 o rt h ep r e s e n c eo f
symptomatic HIV disease. CD4 cell counts were
determined with a FACScount apparatus (Becton Dick-
inson) in freshly collected whole blood.
The local HIV clinic databases and the patients’ medi-
cal records were used to obtain demographic data (eth-
nic origin, country of birth, gender, HIV transmission
risk group, and age at HIV diagnosis), and clinical and
laboratory data (clinical stage at presentation, CD4
count and viral load within three months of HIV diag-
nosis, together with a longitudinal record from initial
diagnosis of all clinical events, serial CD4 cell counts
and viral load, and all ART drug prescriptions). Ethnic
group was based on self-reported ethnicity on the clinic
registration form and country of birth.
At one of the two clinic sites (King’s College Hospital),
adherence to the antiretroviral drug regimen is assessed
routinely at each clinic visit by documenting the number
of times a specific drug dose had been missed, as well as
the number of times it had been taken more than two
hours late over the preceding 30-day period.
Laboratory methods
HIV-1 serotyping was performed on the first available
plasma sample after HIV diagnosis from all patients
using an in-house enzyme linked immunoassay (EIA)
directed against peptide antigens representative of the
V3 region of the outer envelope glycoprotein, gp120
[31], and was used to discriminate between B and non-B
subtypes [32]. Env sequencing was performed to assign a
subtype to samples identified as non-B-using EIA (n =
124) and in samples with mixed reactivity (n = 19) or
non-reactivity (n = 71) on serology. In addition, env
sequencing was performed to validate EIA-determined
subtype B infections in all black Africans, the majority
of black Caribbeans, and in a sample of white patients
with a subtype B infection (n = 30); previous studies
have shown that serological typing can discriminate
between B and non-B subtypes with a high degree of
specificity in populations with predominantly subtype B
infections [31].
Env sequencing was performed at the Dulwich Health
Protection Agency (HPA) or at the HPA Sexually Trans-
mitted and Blood Borne Virus Laboratory, Colindale, Lon-
don. Samples processed at Dulwich HPA were extracted
using QiAamp Viral RNA Mini Kits (Qiagen Ltd, Crawley,
UK) according to the manufacturer’s instructions. Amplifi-
cation and cycle sequencing reactions were carried out as
previously described [11]. Sequencing reactions (1.5 μL)
were run on a Visible Genetics sequencing system under
standard conditions using version 3.1.6 software. Samples
handled at the HPA, Colindale, were extracted using a
modified Boom method [32] and amplification was per-
formed. Sequencing was performed using a CEQ 2000 XL
DNA Analysis System capillary sequencer (Beckman Coul-
ter, High Wycombe, UK) according to the manufacturer’s
instructions.
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lysis of env gene alignments. HIV-1 reference sequences
representative of group M subtypes (A-K), the most
common CRFs, and groups O and N were obtained
from the Los Alamos HIV sequence database http://
www.hiv.lanl.gov/. Alignments of the study (where at
least 240 base pairs [bp] of unambiguous sequence were
available) and reference sequences were generated using
the latest version of CLUSTAL W http://www.ebi.ac.uk/
clustalw/ within Bioedit v4.8.5. The parameters of the
optimal model of evolution were estimated using Mod-
eltest v3.0 within the phylogenetic analysis package Phy-
logenetic Analysis Using Parsimony (Paup*), and
neighbor-joining trees (bootstrapped × 1000) were gen-
erated. The tree topology was used to assign subtypes
based on a high level of bootstrap support (> 70%) for
each subtype or CRF cluster.
When a phylogenetically determined subtype was
available, this was used to assign a definitive subtype.
Two further subtyping methods were applied as a vali-
dation of the phylogenetic analysis results and to enable
a subtype to be assigned to samples for which phyloge-
netic analysis was not possible: the National Center for
Biotechnology Information Retrovirus Genotyping Tool
(http://www.ncbi.nlm.nih.gov/projects/genotyping/ with
a window size of 100 bp and an increment step of 50
bp; and the Basic Local Alignment Search Tool (BLAST
2.0) search tool at Los Alamos database http://www.hiv.
lanl.gov/content/sequence/BASIC_BLAST/basic_blast.
html.
Algorithm for assignment of HIV-1 subtype
We developed a final algorithm to incorporate serology
and genotypic subtype. Where an HIV-1 subtype was
available by genotyping (n = 289; 221/345 of non-B sub-
types; 68/407 of B subtypes), this was used to assign
subtype. Where an HIV-1 sequence subtype was not
available, as was the case with most B subtypes, an EIA-
defined subtype B infection was assigned (n = 463; 339/
407 B subtype; 124/345 non-B subtype). Because serol-
ogy is unreliable for discriminating between B and non-
B subtype in low subtype B prevalence populations such
as black Africans [33], only subtype B infections in black
Africans that had been confirmed by sequencing were
included in the analysis.
Statistical methods
We compared the demographic, clinical and laboratory
characteristics at HIV diagnosis among patients infected
with subtype B and the four main non-B subtypes (A, C,
D and CRF02-AG), using chi-squared tests for categori-
cal variables, and either Kruskal-Wallis or Wilcoxon
rank-sum tests for continuous variables. We first com-
pared subtype B with all non-B infections combined,
and then conducted a series of pair-wise comparisons
for the individual non-B subtypes.
We first compared the rate of CD4 cell decline prior to
starting antiretroviral therapy in patients infected with B
and non-B subtypes (A, C, D and CRF02-AG) based on
their pre-therapy longitudinal CD4 cell count profiles. The
rate of decline in square root transformed CD4 cell count
for each subtype was estimated and compared using two-
level random effects multiple regression models, and for
four other variables (ethnicity, gender, HIV risk group and
age). This model recognizes that the data are series of
CD4 cell counts from the same individual over time, and
allows each individual to have his or her own estimated
intercept and rate of decline by introducing patient-speci-
fic elements (random effects). Multivariable regression
analysis was used to examine for independent predictors
of rate of CD4 decline using a backward elimination pro-
cedure. As the date of infection was not known in the
majority of cases, all multivariate analyses were adjusted
for the baseline CD4 cell count.
We also compared the time to virological suppression <
400 copies/ml following initiation of highly active antire-
troviral therapy (HAART) and the time to virological
rebound (based on two consecutive viral loads of > 400
copies/ml) after initial suppression, using Kaplan-Meier
estimation. Log-rank tests were used to analyze pair-wise
differences between subtypes, and all analyses were
adjusted for percent adherence. Percent adherence was
calculated for each patient visit by dividing the total num-
ber of missed or late doses by the total number of doses
prescribed over a 30-day period, multiplied by 100. Per-
cent adherence was analyzed as a binary variable (100%
adherent vs. < 100% adherent); less than 100% adherence
is associated with a significant reduction in attainment
and maintenance of viral load suppression [34].
Univariate logistic regression analysis was used to
examine the association between adherence and subtype,
as well as other variables, including gender, risk groups
and ethnicity, for each visit up to three visits. A general-
ized estimating equation (GEE) model for binary out-
come with an exchangeable correlation matrix was also
used to examine the relationship between adherence
and subtype, incorporating up to three adherence assess-
ments. Patients with more than one visit were used to
examine changes in adherence overtime. A further ana-
lysis using a GEE model with an exchangeable correla-
tion matrix was also performed for the subgroup of 94
patients with at least two adherence assessments. All
data were analyzed using Stata 7.5 (Stata Corp., College
Station, Texas, USA).
Results
Characteristics of 679 patients infected with B and non-B
subtypes, A, C, D, and CRF02-AG
Of 861 patients, 182 patients were excluded from the
analysis because their subtype could not be determined
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unspecified non-B subtype (n = 16); less common non-B
subtypes (n = 34); and incomplete epidemiological data
(n = 23, 13 B, 4 A, and 6 C). Table S1, Additional file 1
shows the demographic, clinical and laboratory charac-
teristics at HIV diagnosis of 679 patients infected with
either subtype B (n = 394) or the four most common
non-B subtypes - C (n = 125), A (n = 84), D (n = 51),
or CRF02-AG (n = 25) - for whom complete epidemio-
logical data was available. Of the 679 patients, 208
(30.6%) were female, 230 (33.9%) were black African,
301 (44.3%) had heterosexually acquired infection, and
t h em e d i a nC D 4c o u n ta n dv i r a ll o a da td i a g n o s i sw a s
315 (IQR = 164-481) and 12,400 (IQR = 1706-54,633),
respectively. There were no statistically significant differ-
ences in the gender, ethnic group or risk group between
the 679 and those excluded from the analysis.
Fifty-eight of 357 whites (16.2%) were infected with
non-B subtypes (19 with subtype A, 16 with C, eight
with D, and three with CRF02-AG). Of the 230 black
Africans, only 11 (4.8%) were infected with B subtype,
and the most common non-B subtypes were C (98,
42.6%), A (61, 26.5%), D (40, 17.4%), and CRF02-AG
(20, 8.7%). Of the 51 black Caribbeans, 38 (74.5%) were
infected with B subtypes, and 13 (25.5%) with non-B
subtypes (seven with C, three with A, two with D, and
one with CRF02-AG).
There were no statistically significant differences
between the non-B subtypes in demographic characteris-
tics or stage of disease at presentation. However, com-
pared to those infected with any of the four non-B
subtypes, patients with subtype B were more than twice
as likely to be male (89.1% vs. 35.3% to 48%) (all p <
0.001), to be white (78.9% vs. 2.8% to 22.6%) (all p <
0.001), and to be homosexual or bisexual versus hetero-
sexual (74.4% vs. 6.4% to 15.5%) (all p < 0.001). The
median CD4 cell count at HIV diagnosis was signifi-
cantly lower in patients infected with non-B versus B
subtype: 331 (IQR = 196-501) cells/mm
3 versus 250
(IQR = 100-449) in subtype A (p = 0.02), 250 (IQR =
141-413) in subtype C (p = 0.01), 249 (IQR = 30-508) in
subtype D (p = 0.04), and 297 (IQR = 113-386) with
CRF02-AG (p = 0.06). There were no statistically signifi-
cant differences in the median age or viral load at HIV
diagnosis, or in the type of ART regimen between B and
a n yo ft h en o n - Bs u b t y p e s( A ,C ,Da n dC R F 0 2 - A G )o n
pair-wise comparisons.
Rate of CD4 cell change prior to antiretroviral therapy
We analyzed 2778 CD4 cell counts in 627 patients, after
exclusion of 52 patients who had only a baseline CD4
count available. A median of six serial CD4 cell counts
were available in 627 patients prior to the initiation of
any antiretroviral therapy (representing 77.4% of subtype
B, 73.8% of subtype A, 76% of subtype C, 76.5% of
subtype D, and 72% of CRF02-AG). The median six-
monthly decline in the square root transformed CD4
cell count was -0.22 (95% CI, -0.29, -0.15) for subtype B
and -0.27 (-0.37, -0.16) for all non-B subtypes combined.
However, there were non-B subtype-specific differences
in the rate of CD4 change: -0.22 (-0.40, -0.05) for sub-
type A; -0.21 (-0.40, -0.04) for subtype C; -0.80 (-1.08,
-0.52) for subtype D; and -0.01 (-0.42, 0.40) for CRF02-
AG.
There were no statistically significant differences in
the rate of CD4 decline between B versus A (p = 0.24)
or B versus C (p = 0.99). However, subtype D-infected
patients had a four-fold more rapid rate of CD4 decline
compared with subtypes B, A and C (unadjusted p
values: B vs. D, p = 0.05; A vs. D, p = 0.002; C vs. D, p
= 0.05; and CRF02-AG vs. D, p = 0.01). There was no
association between rate of square root CD4 cell decline
and ethnicity, gender risk group or age. The faster rate
of CD4 decline in subtype D compared to other major
subtypes remained significant after adjustment for ethni-
city, gender and baseline CD4 cell count (B vs. D, p =
0.02; A vs. D, p = 0.002; C vs. D, p = 0.05; CRF02-AG
vs. D, p = 0.01).
Time to virological suppression < 400 copies/ml following
initiation of HAART
Overall, 374 of 679 study patients commenced antiretro-
viral therapy; 217 were subtype B, 46 were subtype A, 68
were subtype C, 29 were subtype D, and 14 were
CRF02-AG. Of these, 141 received a protease inhibitor
(PI) based combination, 109 a non-nucleoside reverse
transcriptase (NNRTI) based regimen, 98 a triple
nucleoside reverse transcriptase (NRTI) regimen, and 26
an NNRTI and PI combination. There were no differ-
ences in the type of regimen across subtypes, although a
higher proportion of CRF02-AG patients received a PI-
based regimen. We found no significant differences
between subtypes B, A, C, D and CRF02-AG in the time
to achieve viral load suppression (< 400 copies/ml) after
initiation of HAART (see Figure 1).
The Kaplan-Meier estimates for the percentage
achieving viral load suppression at six, nine and 12
months was, respectively: 66%, 78% and 88% for subtype
B; 77%, 81% and 88% for subtype A; 82%, 85%, 92% for
subtype C; 78%, 88% and 88% for subtype D; and 65%,
65% and 74% for CRF02-AG. Pair-wise comparisons of
viral load suppression for subtypes found no statistically
significant differences (B vs. A, p = 0.98; B vs. C, p =
0.24; B vs. D, p = 0.98; B vs. CRF02-AG, p = 0.40; A vs.
C ,p=0 . 3 2 ;Av s .D ,p=0 . 8 1 ;Av s .C R F 0 2 - A G ,p=
0.84; C vs. D, p = 0.75; C vs. CRF02-AG, p = 0.56; D vs.
CRF02-AG, p = 1.00). The findings were similar after
adjusting for important confounders, such as HIV risk
group, baseline viral load and CD4 cell count, type of
HAART regimen, and levels of adherence.
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ence assessment was available for at least one visit in
148 patients (this was 66/217 (30.4%) for B; 11/46
(23.9%) for A; 25/68 (36.8%) for C; 15/29 (51.7%) for D;
and 5/14 (35.7%) for CRFO2-AG), for two visits in 94
and three visits in 53 patients. In this subgroup, the per-
centage of patients with 100% adherence at the first,
second and third adherence assessments across all sub-
types was 73 (49.3%), 57 (60.6%), and 32 (60.4%), respec-
tively. We found no statistically significant differences
across subtypes in the percentage with 100% adherence
at the three visits, and no association between 100%
a d h e r e n c ea n ds u b t y p e( p>0 . 5 ) ,e t h n i c i t y ,g e n d e ro r
risk group. The findings were similar when the analysis
was repeated using a GEE model with an exchangeable
correlation matrix incorporating all three adherence
assessments.
Time to virological rebound following initial viral load
suppression < 400 copies/ml
Of the 133 subtype B patients who attained an initial
viral load of < 400 copies/ml after initiation of HAART,
67 (45%) experienced subsequent viral load rebound by
12 months (defined as two consecutive counts of > 400
copies/ml) (see Figure 2). The percent of virological
rebound at six months after initial viral load suppression
was similar across subtypes B (45%), A (35%), C (34%)
and CRF02-AG (44%), but significantly higher, at 70%,
for subtype D (B vs. D, p = 0.02; A vs. D, p = 0.004; C
vs. D, p = 0.01; D vs. CRF02-AG, p = 0.37).
In a Cox proportional hazards model, subtype D ver-
sus B infection and < 100% adherence were the only fac-
tors independently associated with an increased rate of
virological rebound (Hazard Ratio [HR] = 2.14, 95% CI
= 1.12-4.14, p = 0.02; HR = 1.32, 95% CI = 1.09-1.59, p
= 0.004) after adjustment for baseline CD4 count and
viral load, risk group and ethnicity. In contrast, subtype
A versus B infection was associated with a reduced risk
of viral rebound (HR = 0.67, 95% CI = 0.46-0.98, p =
0.039).
Discussion
Our study was based on a large, well-characterized and
ethnically diverse HIV-1-infected cohort in south Lon-
don, half of whom were infected with the four main
non-B subtypes (A, C, D and CRF02-AG), and with
similar access to HIV care and monitoring and antire-
troviral therapy. Although we found no clinically or sta-
tistically important differences in either the rate of
immunological progression prior to antiretroviral ther-
apy or in the initial virological response to antiretroviral
therapy between subtype B and all non-B subtypes com-
bined, certain non-B subtype-specific differences were
observed. In particular, subtype D infection was asso-
ciated with both a statistically significant four-fold faster
rate of CD4 decline and a higher rate of virological
rebound on ART compared with subtype B and the
other main non-B subtypes, A and C.
We considered carefully whether the more rapid
immunological progression in subtype D-infected
patients than in patients with other subtypes could be
explained by the shorter follow up, fewer CD4 cell
count measurements and other differences in demo-
graphic characteristics. However, the faster rate of CD4
decline among subtype D patients remained statistically
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important confounding factors, including gender, risk
group, ethnic group and age. A further limitation of this
and other studies on the impact of subtype on disease
progression is that date of HIV infection was unknown.
However, the baseline CD4 cell count, a surrogate for
duration of infection, was similar across the non-B sub-
types, but lower compared to B subtype infection [35],
consistent with the more advanced disease at clinical
presentation among black Africans who are more likely
to be infected with non-B subtypes; this was adjusted
for in the multivariate analysis.
Our study is the first from an industrialized country
and including white patients infected with non-B sub-
types to show a faster rate of disease progression with
subtype D infection. This is consistent with the find-
ings from five sub-Saharan African cohort studies
[16,22-25]. In a study of 164 HIV-infected persons in
Uganda (117 with incident infections), of which 65
were subtype A and 99 were subtype D, the relative
hazard of AIDS-free survival was 1.39 (95% CI, 0.66-
2.94, p = 0.39) for subtype D versus A. Those infected
with subtype D and A/D recombinants also had a
more rapid CD4 T cell decline, although this did not
attain statistical significance [14]. In a further study
from Uganda based on 1045 participants in a rando-
mized controlled trial, subtype D was associated with a
1.29-fold increased risk of progression to death com-
pared with subtype A [22]. Similarly, in the third
Ugandan study based on 350 seroincident patients, the
adjusted hazards for AIDS progression for subtype D
was 2.13 (95% CI = 1.20-4.11) and for death 5.65 (95%
C I=1 . 3 7 - 2 3 . 4 )r e l a t i v et os u b t y p eD[ 2 5 ] .Af u r t h e r
seroincident female cohort also found a two-fold
higher mortality and rate of CD4 decline. These differ-
ences could not be explained by a higher viral load
either at set point or over time [24].
Our findings of a similar rate of disease progression
between subtypes B, A, C and CRF02-AG, are also con-
sistent with those epidemiological studies that have
examined for differences between these subtypes
[15,17,19,20]. In one study, based on 126 individuals liv-
ing in Sweden and infected with subtypes A, B, C and D
[17], there were no statistically significant differences in
the rate of CD4 cell decline or in the rate of clinical
progression, although there was a small trend towards a
faster rate of CD4 decline among subtype D-infected
patients. In another cohort study of 91 Israeli men
infected with subtype B and 77 Ethiopian immigrants
infected with subtype C, the rate of change in CD4 per-
centage in the first two years following diagnosis was
the same, -2.2%, for both groups [19]. In a cohort study
of 336 patients from Cameroon and Senegal with
approximately two years’ follow up, there was no differ-
ence in survival, clinical disease progression and rate of
CD4 decline between 207 patients with the CRF02-AG
strain and the 128 patients infected with other strains
(mainly A, n = 59; F, n = 17; and G, n = 15), followed
by subtype C and D (each n = 10) [20]. Other studies
from Thailand have compared subtypes B and E. In 130
seroconverters (103 with subtype E and 27 with subtype
B), the viral load, CD4 and CD8 cell counts recorded
one year after infection were similar in persons infected
with either subtype, although the initial viral load at
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infected with subtype E [15].
Subtype-specific differences in virological and immu-
nological characteristics may account for a faster rate of
CD4 decline in subtype D-infected patients through an
impact on viral load, viral tropism, syncytia formation
and fitness, or immune response [3,12,14]. Although
one study reported that subtype D-infected patients had
higher viral loads during the course of infection than
those with subtype A [36], we found no statistically sig-
nificant differences in baseline or follow-up viral loads
prior to initiation of antiretroviral therapy.
Viral genetic variation can influence phenotypic prop-
erties, such as cell tropism, co-receptor usage and the
ability to form syncytia, although these properties have
only recently been correlated with viral subtype. There
is some evidence that subtype C uses only the CCR5
co-receptor, and has a preponderance of R5 or NSI
viruses and a relative lack of X4 or SI viruses [37,38],
w h i l es u b t y p eDi s o l a t e st e n dt oh a v eah i g h e rf r e -
quency of syncytium formation, CXCR4 (X4) coreceptor
usage and rapidly replicating virus compared with other
subtypes [39]. In a recent study of 31 Ugandan patients
infected with subtype A and 35 with subtype D, there
was a higher probability of X4 or dual tropic viruses in
AIDS-free subtype D patients, which were also more
replication competent. This suggests that an earlier
switch to X4 virus with subtype D may explain the fas-
t e rr a t eo fC D 4d e c l i n ea n dd i s e a s ep r o g r e s s i o nw i t h
subtype D [36].
In our study, HIV-1 subtype was determined by a
combination of EIA and env sequencing, and an algo-
rithm was devised to assign subtype. To clearly identify
whether a sequence belonged to a subgroup represent-
ing a CRF within a certain subtype, phylogenetic analysis
was done for each sequence individually. Significant
misclassification in the assignment of subtype is unlikely
as the majority of non-B subtype was assigned based on
sequencing and phylogenetic analysis. The use of serolo-
gically defined subtype was mainly confined to subtype
B infection among whites, as serotyping has been shown
to be of good specificity for differentiating subtype B
from non-B infections in populations predominantly
infected with B subtype [31]. However, it is acknowl-
edged that classification of subtype based on env or gag
sequencing does not fully represent all aspects of the
genetic variability of HIV, particularly the relationship
to phenotypic properties, and that there may be other
virological strain differences not captured by HIV-1
subtype.
We found no differences in the initial virological
response to HAART, and in the proportion achieving a
suppressed viral load six months after initiation of
HAART according to subtype. This is consistent with
the findings from three other cohort studies that com-
pared the virological response to antiretroviral therapy
based on HIV-1 subtype [26-29]. In a comparison of
265 European and 97 African patients (36% subtype D,
34% subtype C, and 13% subtype A), the initial virologi-
cal and immunological responses were similar [26].
Similarly, in an analysis of 389 whites and 135 non-
whites (mainly infected with non-B subtypes) in Den-
mark, and in 317 subtype B and 99 non-B-infected
patients in France, there were no differences in the per-
centage who achieved viral load suppression of < 400
copies/ml [27,29]. However, neither of these studies per-
formed any subtype-specific analyses across the different
non-B subtypes, although in 113 children participating
in the PENTA 5 clinical trial, HIV-1 subtype (16 A, 44
B, 47 C and 10 D) was not associated with virological
outcomes at 24 and 48 weeks after initiation of HAART
[28]. In a more recent analysis based on data from the
UK Collaborative Group on HIV Drug Resistance and
the UK Collaborative HIV Cohort Study [30], viral sup-
pression occurred more rapidly in patients infected with
subtype C (HR = 1.16, 95% CI = 1.01-1.33, p = 0.04)
and subtype A (HR = 1.35, 95% CI = 1.04-1.74, p =
0.02) relative to subtype B infection, even after adjust-
ment for lower baseline viral load in these subtypes.
Our study is the first to find a higher rate of rebound
for subtype D (70% at 12 months compared to < 45% for
all other subtypes), although this was based on only 11
patients with subtype D infection. Differences in antire-
troviral compliance may also have contributed, although
i no u rs t u d y ,w h e r ea d h e r e n c ed a t aw a sa v a i l a b l eo na
subgroup of patients, we found no difference in levels of
adherence according to either ethnic group or subtype.
I nt h em u c hl a r g e rU Ka n a l y s i s[ 3 0 ] ,w i t ho v e r a l ls i g -
nificantly lower rates of viral rebound, there was a slight
increased risk of viral load rebound from < 50 copies/ml
only among patients infected with subtype C (and not
subtype D) relative to subtype B, even after adjustment
for probable non-adherence (adjusted hazards ratio,
1.40; 95% CI = 1.00-1.95, p = 0.05). In addition to the
researchers’ larger sample size, other important differ-
ences from our study were a different definition of viral
load suppression and rebound, with overall lower rates
of viral rebound.
There is increasing data on subtype-specific variations
in susceptibility to antiretroviral drugs [12,14], with some
well-documented differences in the resistance mutational
patterns to specific drugs according to subtype
[14,40-43]. Therefore, a further explanation for the
higher rate of virological failure among patients with sub-
type D infection might be an increased propensity for the
development of resistance to certain drugs. For example,
recent data suggests that subtype D more easily develops
resistance to non-nucleoside reverse-transcriptase
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and the emergence of the D30N mutation to nelfinavir is
favoured also in subtype D [40]. In the HIVNET 012 trial
of single-dose nevirapine for prevention of mother to
child transmission, nevirapine resistance mutations were
present in 35.7% of subtype D compared to 19% with
subtype A (p = 0.0035) [44]. This is further supported by
a study from Argentina that demonstrated differential
genetic barriers between subtypes leading to different
rates of emergence of drug resistance-related mutations
[47,48]. Importantly, we were unable to demonstrate any
differences in the rate of virological failure for NNRTIs
versus PIs across different subtypes.
Conclusions
There is now a clear consensus that there is a similar
rate of progression and response to HAART for subtype
B and the non-B subtypes, A and C, but that subtype D
is associated with a faster rate of disease progression.
Our study is the first to report a higher rate of treat-
ment failure for subtype D infection, but this will
require confirmation in a larger cohort of patients
infected with different subtypes and receiving antiretro-
viral therapy, with longitudinal data on adherence.
Other detailed virological and immunological studies are
needed to provide insights into the molecular mechan-
isms accounting for the apparent greater virulence of
subtype D infection and potential implications for clini-
cal management.
Additional file 1: Table S1. Characteristic of 679 patients infected with
subtypes B, A, C, D and CRF02-AG.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1758-2652-13-4-
S1.DOC]
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